Compare PACK & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PACK | RLMD |
|---|---|---|
| Founded | 1972 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 303.3M | 319.7M |
| IPO Year | 2017 | 2012 |
| Metric | PACK | RLMD |
|---|---|---|
| Price | $3.82 | $7.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $6.50 | ★ $12.40 |
| AVG Volume (30 Days) | 448.3K | ★ 1.3M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.28 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $395,000,000.00 | $13,070.00 |
| Revenue This Year | $9.29 | N/A |
| Revenue Next Year | $8.35 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 7.08 | ★ 154.83 |
| 52 Week Low | $2.91 | $0.27 |
| 52 Week High | $6.31 | $7.65 |
| Indicator | PACK | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 48.14 | 63.70 |
| Support Level | $3.36 | $3.49 |
| Resistance Level | $5.78 | $7.41 |
| Average True Range (ATR) | 0.17 | 0.44 |
| MACD | 0.10 | 0.02 |
| Stochastic Oscillator | 80.53 | 72.12 |
Ranpak Holdings Corp is a provider of environmentally sustainable, systems-based, product protection solutions for e-Commerce and industrial supply chains. The company offers a full suite of protective packaging systems and paper consumables. The group generates revenue by providing its PPS systems and paper consumables to customers, which include direct end-users and a network of exclusive paper packaging solution distributors, and by providing end-of-line automation systems that solve challenges, including optimization, customization, and efficiency. It has two segments, North America and Europe/Asia.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.